Clinical Trial Update: INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use

View source ↗

Summary

A real-world evidence study (INTERSTELLAR) evaluating lupus outcomes in patients treated with anifrolumab, sponsored by AstraZeneca.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus (SLE) | Status: RECRUITING